title: Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
abstract: Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.
authors.affiliation: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Bor-Sheng
authors.initials: BS
authors.lastname: Ko
authors.forename: Cheng-Shyong
authors.initials: CS
authors.lastname: Chang
authors.forename: Ming-Chih
authors.initials: MC
authors.lastname: Chang
authors.forename: Tsai Yun
authors.initials: TY
authors.lastname: Chen
authors.forename: Tzeon-Jye
authors.initials: TJ
authors.lastname: Chiou
authors.forename: Chang-Fang
authors.initials: CF
authors.lastname: Chiu
authors.forename: Wen-Li
authors.initials: WL
authors.lastname: Huang
authors.forename: Woei-Yau
authors.initials: WY
authors.lastname: Kao
authors.forename: Yii-Jenq
authors.initials: YJ
authors.lastname: Lan
authors.forename: Shen-Fung
authors.initials: SF
authors.lastname: Lin
authors.forename: Tran-Der
authors.initials: TD
authors.lastname: Tan
authors.forename: Jih-Luh
authors.initials: JL
authors.lastname: Tang
authors.forename: Cheng-Hwai
authors.initials: CH
authors.lastname: Tzeng
authors.forename: Po-Nan
authors.initials: PN
authors.lastname: Wang
authors.forename: Su-Pen
authors.initials: SP
authors.lastname: Yet
authors.forename: Hwei-Fang
authors.initials: HF
authors.lastname: Tien
mesh_terms: D015913:Chelation Therapy / Q000379:methods; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D016019:Survival Analysis; D013624:Taiwan / Q000453:epidemiology
chemical_list: D007502:Iron Chelating Agents